Better cardiovascular outcomes of type 2 diabetic patients treated with GLP-1 receptor agonists versus DPP-4 inhibitors in clinical practice

Overview of attention for article published in Cardiovascular Diabetology, June 2020

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 28 Dimensions

Readers on

mendeley: 52 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 28 publications that cite this research output.

28

The most recent citing publications are shown below. View all 28 publications that cite this research output on Dimensions.

Cardiovascular and mortality benefits of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide 1 receptor agonists as third-step glucose-lowering medicine in patients with type 2 diabetes: a retrospective cohort analysis

Article in BMJ Open Diabetes Research & Care (May 2024)

Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Hospitalization for Heart Failure and Amputation Rate Compared With Incretin-Based Therapy in Patients With Diabetic Foot Disease: A Nationwide Population-Based Study

Article in Endocrine Practice (February 2024)

Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease

Article in Cardiovascular Diabetology (November 2023)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.